Free fundraising diagnostic

Founder Delusion Index

Measure the gap between founder conviction and investor-grade evidence before the market does it for you.

A first-pass diagnostic from Venture Stage Lens. No deck upload, no AI judgment, no false precision. Just a sharper view of where investor belief may break.

Before your next investor meeting

Where does the evidence stop and the belief begin?

Get your fundraising reality check, two priority weaknesses and a practical next step.

12 questions. About 4 minutes. Free results after email submission.

Ambition is not the problem. Unsupported ambition is.

The index tests how much of the fundraising story depends on assumptions an investor would have to defend internally.

Claims

Are the claims specific, measurable and relevant to an investment decision?

Evidence

Does the company have contracts, usage, paid pilots, regulatory feedback or third-party proof?

Investment logic

Can an investor explain and defend the case when the founder leaves the room?

Get your free score

Choose the answer that best reflects today. Your score and two priority weaknesses are revealed after you submit your email.

Your fundraising reality check

Your two priority weaknesses

Your answers flag where to look. The next step is to test those claims against your actual deck and evidence.

Build my investor evidence plan

0 of 12 answered

1. Your strongest customer evidence is:

Signed recurring contracts or repeat paid usage Paid pilots with named decision-makers LOIs, verbal interest or unpaid pilots Conversations, surveys or advisor feedback

2. Your buyer and budget owner are:

Clearly identified and validated through sales Known, with some buying-process evidence Plausible but not yet validated Still assumed from market logic

3. When you say traction, you mostly mean:

Revenue quality, retention or usage expansion Paid pilots or active pipeline movement Engagement, meetings and qualified interest Press, awards, advisors or community attention

4. This round will fund:

A specific milestone that unlocks the next financing Several milestones with clear priority order Growth and development across many workstreams The amount we think we need to move faster

5. Your main investor risks are:

Named, sequenced and connected to evidence plans Known, but not fully sequenced Discussed informally Mostly handled only if investors ask

6. Your defensibility is best described as:

Evidence-backed moat with durable advantages Emerging advantage with supporting signals A credible thesis that needs proof Mostly based on being early, AI-enabled or visionary

7. If regulation, clinical validation or compliance matters, your plan is:

Documented with external input and decision points Outlined with partial external input Asserted internally Not yet analyzed Not applicable to our business

8. Your financial model is:

Driver-based and tied to evidence-backed assumptions Mostly driver-based with some assumptions untested Top-down but internally coherent A target outcome reverse-engineered into a model

9. For the hardest investor questions, you have:

Direct answers with supporting evidence Good answers with some evidence gaps Narrative answers that need substantiation Confidence that we can handle it live

10. Your next 6-month execution plan is:

Sequenced around value-inflecting milestones Mostly sequenced with some open dependencies A broad operating plan with many parallel priorities Still forming around fundraising needs

11. Third-party validation currently includes:

Contracts, references, data or formal written evidence Named supporters willing to validate key claims Soft endorsements and informal support Mostly internal conviction

12. Your pitch narrative is mainly organized around:

The investment decision and risks removed by capital The business case and upcoming milestones The product, vision and market opportunity Everything impressive about the company

What could hold your round back?

Complete all 12 questions, then enter your email to reveal your score, two priority weaknesses and your next step.

Name (optional) Email Company (optional)

Your email and answers go to Venture Stage Lens to provide your result and follow up about a relevant review. Privacy policy.

What the index catches

Founders rarely lack conviction. The dangerous part is when the pitch treats early signal as if it were decision-grade proof.

Founder claim Hospitals want this.

Investor translation: who owns the budget, what procurement path exists, and is there a signed commitment?

Founder claim Our AI is proprietary.

Investor translation: what is defensible beyond model access, prompts, workflow design or early data?

Founder claim We need a large round to expand.

Investor translation: which specific risk does this capital remove, and what becomes investable afterward?

Founder claim We have strong traction.

Investor translation: is it recurring revenue, paid pilots, usage growth, retention, or mostly enthusiasm?

Paid VSL diagnostic

Turn the score into an investor-ready evidence plan.

An investor meeting is an expensive place to discover an evidence gap. A paid VSL review tests your deck, challenges the claims behind it and turns the gaps into a practical plan before your next round of outreach.

Deck review and claim-to-evidence map
Top unsupported claims and investor red flags
Round size, timing and milestone logic assessment
30/60/90-day evidence plan and debrief session

Investor Evidence Review

Know which claims will face the toughest scrutiny, what proof is missing and what to fix first.

Get a focused assessment of your deck and round logic, a prioritized evidence plan and a debrief to decide your next move. Scope and fee agreed before work begins.

Discuss my VSL review